ArticleJournal of imaging informatics in medicine2026
Development and Validation of an Explainable MRI-Based Habitat Radiomics Model for Predicting p53-Abnormal Endometrial Cancer: A Multicentre Feasibility Study.
Article in Journal of imaging informatics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Noninvasive prediction of TP53 mutation in prostate cancer based on advanced diffusion weighted imaging.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We developed an MRI-based habitat radiomics model (HRM) to predict p53-abnormal (p53abn) molecular subtypes of endometrial cancer (EC). Patients with pathologically confirmed EC were retrospectively enrolled from three hospitals and categorized into a training cohort (n = 270), test cohort 1 (n = 70), and test cohort 2 (n = 154). The tumour was divided into habitat sub-regions using diffusion-weighted imaging (DWI) and contrast-enhanced (CE) images with the K-means algorithm. Radiomics features were extracted from T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), DWI, and CE images. Three machine learning classifiers-logistic regression, support vector machines, and random forests-were applied to develop predictive models for p53abn EC. Model performance was validated using receiver operating characteristic (ROC) curves, and the model with the best predictive performance was selected as the HRM. A whole-region radiomics model (WRM) was also constructed, and a clinical model (CM) with five clinical features was developed. The SHApley Additive ExPlanations (SHAP) method was used to explain the outputs of the models. DeLong's test evaluated and compared the performance across the cohorts. A total of 1920 habitat radiomics features were considered. Eight features were selected for the HRM, ten for the WRM, and three clinical features for the CM. The HRM achieved the highest AUC: 0.855 (training), 0.769 (test1), and 0.766 (test2). The AUCs of the WRM were 0.707 (training), 0.703 (test1), and 0.738 (test2). The AUCs of the CM were 0.709 (training), 0.641 (test1), and 0.665 (test2). The MRI-based HRM successfully predicted p53abn EC. The results indicate that habitat combined with machine learning, radiomics, and SHAP can effectively predict p53abn EC, providing clinicians with intuitive insights and interpretability regarding the impact of risk factors in the model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.